In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer. - Wikidata - wikimedia - TriplyDB

In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer.

In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer.

http://www.wikidata.org/entity/Q35250612

about

p38MAPK and Chemotherapy: We Always Need to Hear Both Sides of the Story Predictive biomarkers of sorafenib efficacy in advanced hepatocellular carcinoma: Are we getting there?Biological features and biomarkers in hepatocellular carcinoma Regorafenib: Antitumor Activity upon Mono and Combination Therapy in Preclinical Pediatric Malignancy Models Combination treatment including targeted therapy for advanced hepatocellular carcinoma Genetically engineered mouse models in oncology research and cancer medicine Inhibition of the prolyl isomerase Pin1 enhances the ability of sorafenib to induce cell death and inhibit tumor growth in hepatocellular carcinoma.High-throughput functional genomics using CRISPR-Cas9.Impact of neo-adjuvant Sorafenib treatment on liver transplantation in HCC patients - a prospective, randomized, double-blind, phase III trial.Decreased miR122 in hepatocellular carcinoma leads to chemoresistance with increased arginine.Upregulation of MicroRNA-19b predicts good prognosis in patients with hepatocellular carcinoma presenting with vascular invasion or multifocal disease Screening for tumor suppressors: Loss of ephrin receptor A2 cooperates with oncogenic KRas in promoting lung adenocarcinoma.Activation of c-Jun predicts a poor response to sorafenib in hepatocellular carcinoma: Preliminary Clinical Evidence In vivo RNAi screens: concepts and applications.Iron-Oxide-Based Nanovector for Tumor Targeted siRNA Delivery in an Orthotopic Hepatocellular Carcinoma Xenograft Mouse Model Prp19 facilitates invasion of hepatocellular carcinoma via p38 mitogen-activated protein kinase/twist1 pathway.Armored long non-coding RNA MEG3 targeting EGFR based on recombinant MS2 bacteriophage virus-like particles against hepatocellular carcinoma.Downregulation of amplified in breast cancer 1 contributes to the anti-tumor effects of sorafenib on human hepatocellular carcinoma.Alpha fetoprotein antagonises benzyl isothiocyanate inhibition of the malignant behaviors of hepatocellular carcinoma cells.Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitors.Compromised MAPK signaling in human diseases: an update.MEK 1/2 inhibitors in the treatment of hepatocellular carcinoma.Opportunities and challenges provided by crosstalk between signalling pathways in cancer.Advances in targeted therapies for hepatocellular carcinoma in the genomic era.Transgenic mouse models generated by hydrodynamic transfection for genetic studies of liver cancer and preclinical testing of anti-cancer therapy.Biological Networks Governing the Acquisition, Maintenance, and Dissolution of Pluripotency: Insights from Functional Genomics Approaches.Targeting the PD-L1/DNMT1 axis in acquired resistance to sorafenib in human hepatocellular carcinoma Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma Stromal cell-derived factor-1 (SDF-1) as a target in liver diseases.The BH3-only protein BID impairs the p38-mediated stress response and promotes hepatocarcinogenesis during chronic liver injury in mice.Identification and Optimization of Combinatorial Glucose Metabolism Inhibitors in Hepatocellular Carcinomas.Transcriptional repression of IFNβ1 by ATF2 confers melanoma resistance to therapy.ATF2, a paradigm of the multifaceted regulation of transcription factors in biology and disease.Hepatocellular carcinoma treatment: a comparative review of emerging growth factor receptor antagonists.Technical Improvement and Application of Hydrodynamic Gene Delivery in Study of Liver Diseases.MicroRNA pharmacogenomics based integrated model of miR-17-92 cluster in sorafenib resistant HCC cells reveals a strategy to forestall drug resistance.Comment on "combination treatment including targeted therapy for advanced hepatocellular carcinoma".Molecular Pathogenesis of Hepatocellular Carcinoma.The p38 pathway, a major pleiotropic cascade that transduces stress and metastatic signals in endothelial cells.Expression of pERK and VEGFR-2 in advanced hepatocellular carcinoma and resistance to sorafenib treatment.

P2860

Q26742078-2A5C330F-F6AF-4AA6-B71C-0EF5E2AA1253 Q26784218-2913D081-5D0E-4DE8-A37C-E1668EFD2D42 Q26799462-C657B938-9CB3-45AC-85E1-0F6E3C65223C Q27345024-186FA898-6527-4046-B98B-3828AC00E10F Q28077738-8EEDFB15-B183-4AE1-B605-5816921BB025 Q28079323-1B5A5CCD-5739-4F86-A761-C03115C7296D Q33728138-C9FDC772-CD54-4334-A6D3-7430E485E011 Q35597703-BC7E8432-4003-48FA-8A93-755C8EAA5865 Q35625989-B7EFE649-B013-48C2-AB9D-81290EA48FCB Q35781589-2CF92AE7-B26D-4958-8660-3FB737BB9E6A Q35802368-AD4E8A27-0AA3-4F77-88EF-55D71B7FB135 Q36331953-02A0811D-9812-4DED-ADDF-762D9953566E Q36675015-71729F15-8E72-4D7B-9C9C-822EAC7AD6DF Q36736715-8CBF0864-C99D-41A0-9B1C-771C12844123 Q36792563-3D39E884-098F-433E-A4F8-58A6DCC5FF7C Q37225447-E8AA2B46-A934-41B8-8C9C-4A71701A3671 Q37269190-3CA7FB7E-435B-4C09-BD4B-5E2FA3911A84 Q37301893-2C2BD5AC-4FE4-4AD2-B2FB-5E8092C55411 Q37689017-22A9F7F2-8787-4F05-8BFA-11E8DB453107 Q37690136-E38BD078-B609-4DF4-87B3-24D484099E7E Q38359194-6935C313-5D53-4D85-9B9D-E717C3DD459F Q38444096-1DD36C99-10F9-4B30-8FAA-B0161EF252FE Q38485894-18540AA9-257D-4FD8-B9C9-C0E584206DC9 Q38521011-ACDCEE46-EEDD-4D89-BEE1-8F1A6C0852C0 Q38556534-9915423C-52B9-4065-9159-F969D0326B5E Q38638128-0C5E1366-4E98-4F6E-B8B1-DD79A790C4D7 Q38719539-09C03E6E-D2C0-44CC-B91A-6297C9E7E89A Q38812372-FB542960-543D-4232-B9F3-C7D4D59E3167 Q38867913-7C840629-ADEB-46FB-B227-B602D6A9A4D5 Q38878026-F3F41444-29F6-49B4-8DD9-E14224074F65 Q38893018-4F5E17E4-2213-4B52-86A5-A8E500A6E7B2 Q38904811-6DA8FC84-9ACA-41BC-9CBC-843D78C1AC3D Q39141159-CC137D20-DDE2-46F9-ACDB-DA2BAE39A8F8 Q39307416-C7870D30-71BD-48C6-B24B-4CBC28B2994C Q40039939-738DE7A0-EF01-4E6D-BBD4-1F115FC95F57 Q41126784-975DCE33-FFEC-47BD-A1F5-E45D3A4F60D1 Q41544681-B9675A53-67A5-4662-9A4A-28627E11578F Q41544729-0644CBE9-E7CC-41DC-AB46-1C27F6CA96C0 Q41547499-26E39F24-E097-4A65-BC86-FF3E4EEBD862 Q41563253-8B6BB808-1047-49A5-A913-84C640441BCC

P2860

In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer.

http://www.wikidata.org/entity/Q35250612

description

2014 nî lūn-bûn

@nan

2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer.

@ast

In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer.

@en

type

label

In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer.

@ast

In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer.

@en

prefLabel

In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer.

@ast

In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer.

@en

P1433

Q35250612-1F41B7D9-FE18-4DAA-9968-CE91D9C8E295

P1476

Q35250612-E7C6709D-D963-416A-A1DA-2FF22ACA3871

P2093

Q35250612-014BD07B-EF46-4957-96AD-510B3355D4DB

Q35250612-04A73977-1D2B-420C-B1FE-D9FDF3B429E0

Q35250612-0B5076A0-9524-4D41-993A-68C78E967A32

Q35250612-33A162F8-7407-49E7-9CD6-28B500F7B344

Q35250612-55908B36-2A8F-4CB1-98D9-DC99A128679E

Q35250612-66896192-6960-4640-91FD-ED2A1BB25341

Q35250612-B23F6D15-F521-496A-B067-EEA7BEFE4422

Q35250612-B541D7CE-7C83-45F3-9522-69739EFCD57E

Q35250612-C1C78EEE-FAEE-4325-A23F-C575A03B4A31

Q35250612-D514FCBB-2D0D-466F-A496-11B53ADE409B

P2860

Q35250612-0018E802-88B9-44DE-BB31-4FABCC91178C

Q35250612-01071685-2633-4526-B410-3BBD5AE4CE45

Q35250612-01939A49-1A17-4192-A761-76518B9320C8

Q35250612-0422ECBB-EFB0-4D00-BD1C-9A3D26157F51

Q35250612-1CFF1B95-F77E-4908-90E4-C3FFF74741C6

Q35250612-212C4433-9C59-4989-AEA8-5C0A7666E359

Q35250612-26E52BD1-0684-4571-B4D9-D00A9C83BEA8

Q35250612-2A3A822B-CA1C-4640-A200-BAE28E0A3CFE

Q35250612-32C6AE56-FD3D-42C7-89F2-0049979C3514

Q35250612-333B58EA-FC33-434D-82A9-5773E961782F

P2888

Q35250612-24C4221F-13FC-4904-992A-540974E089E2

P304

Q35250612-378E5E5D-4ECF-48F1-B069-100B2A5817E7

P31

Q35250612-68112F5E-52F4-4B51-9C07-6D3A2860A952

P356

Q35250612-B5726D26-AD16-4821-BF0B-33DE9191B9D3

P407

Q35250612-8C7033FA-442D-42E0-81BF-A19432661E27

P433

Q35250612-C44E7A00-9B20-4597-BFC1-D9C4B20B4D14

P478

Q35250612-4285E598-E409-44DC-B7EE-CEC109B4441A

P50

Q35250612-40C54D1C-D403-4E1C-8D34-6C465485D7E8

Q35250612-69D7A2EC-6D02-4069-9BC6-BB8C7EE9D9ED

Q35250612-94F24125-BAE8-45E4-906C-71EA7C32B155

Q35250612-A7173F02-54DE-4211-AE62-E1101BD6860C

Q35250612-B2288F56-96F7-43D9-AD89-F00B8203C91A

Q35250612-DB081C55-45CB-414B-B780-EBDF0B2DD50E

Q35250612-E2EEBF0C-749F-4572-9ED6-00986A7B6F2F

P577

Q35250612-2E836210-C369-44B2-B9AE-A27529112D92

P5875

Q35250612-D3E8F8FC-1672-4DE8-92FB-363DAE7CA497

P698

Q35250612-7828B9CE-B1C5-4751-A264-5EBEB055BCED

P932

Q35250612-51F7A79D-E4D9-4CC0-80B2-5B56D3FA6976

P356

P1433

Nature Medicine

P1476

In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer

@en

P2093

Anja Hohmeyer

http://www.w3.org/2001/XMLSchema#string

Anne von Thun

http://www.w3.org/2001/XMLSchema#string

Daniel Dauch

http://www.w3.org/2001/XMLSchema#string

Karl-Heinz Weiss

http://www.w3.org/2001/XMLSchema#string

Lars Zender

http://www.w3.org/2001/XMLSchema#string

Marina Pesic

http://www.w3.org/2001/XMLSchema#string

Nisar P Malek

http://www.w3.org/2001/XMLSchema#string

Peter Schirmacher

http://www.w3.org/2001/XMLSchema#string

Ramona Rudalska

http://www.w3.org/2001/XMLSchema#string

Robert Geffers

http://www.w3.org/2001/XMLSchema#string

P2860

MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling

Skepinone-L is a selective p38 mitogen-activated protein kinase inhibitor

Dibenzosuberones as p38 mitogen-activated protein kinase inhibitors with low ATP competitiveness and outstanding whole blood activity

Sorafenib in advanced hepatocellular carcinoma

Extracellular signal regulated kinase (ERK)/mitogen activated protein kinase (MAPK)-independent functions of Raf kinases

Topoisomerase levels determine chemotherapy responsein vitroandin vivo

Cancer drug resistance: an evolving paradigm

Design of a genome-wide siRNA library using an artificial neural network.

p38 MAP kinases: beyond the stress response.

Somatic integration of an oncogene-harboring Sleeping Beauty transposon models liver tumor development in the mouse

P2888

P304

1138-1146

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NM.3679

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P50

Katherine McJunkin

P577

2014-09-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

265610769

http://www.w3.org/2001/XMLSchema#string

P698

25216638

http://www.w3.org/2001/XMLSchema#string

P932

4587571

http://www.w3.org/2001/XMLSchema#string